Rare diseases
Investigational molecules
Locations
Long‑Term Safety and Efficacy of SPY001-001, SPY002 and SPY003 in Adults with Ulcerative Colitis
FranceA Phase 3 Randomized Study of mRNA‑4157 plus Pembrolizumab as Adjuvant Therapy in Patients with Completely Resected Stage I Non‑Small Cell Lung Cancer
FrancePhase 3 study of ZL-1310 versus topotecan hydrochloride in patients with relapsed small cell lung cancer
FranceStudy of PF-07275315 versus placebo for efficacy and safety in adults with moderate-to-severe chronic obstructive pulmonary disease (COPD)
FrancePhase 3 Randomized, Double‑Blind, Placebo‑Controlled Study of ALKS 2680 for Excessive Daytime Sleepiness in Adults with Narcolepsy Type 2
FrancePhase 3 Randomized Study of ALKS 2680 for Excessive Daytime Sleepiness in Adults with Narcolepsy Type 1
FranceEvaluation of Anifrolumab Subcutaneous Treatment in Immunosuppressant‑Naïve and Biologic‑Naïve Patients with Systemic Lupus Erythematosus
FranceLong-term Safety and Efficacy of Remibrutinib in Adults with Moderate to Severe Hidradenitis Suppurativa
FranceBI 764198 in Adults and Adolescents with Proteinuric Kidney Diseases
FranceOrelabrutinib in Patients with Primary Progressive Multiple Sclerosis
FranceLong-Term Safety and Efficacy of Zasocitinib in Adults with Active Psoriatic Arthritis
FranceA study to evaluate the effectiveness and safety of pridopidine hydrochloride in patients with amyotrophic lateral sclerosis
FranceTell us about your condition – we search every trial in Europe and connect you with the right site.
